Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    PT-141 (Bremelanotide)

    Skin, Hair & Aesthetics

    Status
    FDA Approved
    Evidence

    Not graded on a research bench yet

    PT-141 (bremelanotide) is a cyclic 7-amino-acid synthetic melanocortin receptor agonist that acts centrally in the brain — not peripherally on genital tissue — to improve sexual desire, arousal, and responsiveness.

    Reviewed

    01Overview

    What PT-141 (Bremelanotide) is

    It is the only FDA-approved peptide for a sexual function indication in women: Vyleesi received FDA approval in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as a 1.75 mg subcutaneous autoinjector on-demand approximately 45 minutes before anticipated sexual activity.

    Read the full overviewShow less

    The pharmacology is fundamentally different from the PDE5 inhibitor class (sildenafil, tadalafil, vardenafil). PDE5 inhibitors work peripherally in the corpus cavernosum to maintain erectile blood flow once arousal has already begun. PT-141 works centrally in the hypothalamus, specifically on MC4R-expressing neurons, to create the upstream arousal signal itself. This means PT-141 can address sexual dysfunction that PDE5 inhibitors cannot — most notably desire and arousal disorders where the physiologic machinery is intact but the central arousal trigger is not firing.

    PT-141 evolved from earlier research on Melanotan-II, a broader-spectrum melanocortin agonist originally developed for photoprotective tanning indications. During Melanotan-II trials in the 1990s, an unexpected and consistent side effect emerged: spontaneous erections in male volunteers. Palatin Technologies (the developer) isolated the pharmacophore responsible, removed the pigmentation-driving MC1R activity to the extent possible, and produced bremelanotide — a more selective MC4R agonist with a cleaner side effect profile.

    Clinical trial data from the key RECONNECT Phase 3 program ([Kingsberg et al., 2019]) demonstrated statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) across two 24-week trials enrolling 1,247 premenopausal women with HSDD. Off-label use in men for erectile dysfunction and both sexes for general libido enhancement is widespread in the peptide research community, with typical subcutaneous doses ranging from 0.5 to 2 mg taken 30-60 minutes before anticipated activity.

    The most significant safety considerations are transient blood pressure elevation (typically +6-8 mmHg systolic, resolving within 8-12 hours), nausea (the single most commonly reported adverse event, affecting roughly 40% of users in clinical trials), and — with repeated use — dose-related hyperpigmentation caused by residual MC1R cross-reactivity.

    How it works

    Melanocortin Receptor Pharmacology

    PT-141 is a synthetic cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-DPhe-Arg-Trp-Lys]-OH) that binds the melanocortin receptor family with the following selectivity profile:

    ReceptorPrimary LocationPT-141 ActivityClinical Effect
    MC4RHypothalamus (PVN, LH)High-affinity agonistSexual arousal, appetite suppression
    MC3RLimbic system, hypothalamusModerate agonistEnergy homeostasis
    MC1RSkin melanocytesLow agonist activityDose-related hyperpigmentation (residual)
    MC2RAdrenal cortexNegligibleNo ACTH-like effects
    MC5RSebaceous glandsMinorTrivial sebum effects
    Read the full mechanismShow less

    PT-141 is a non-selective melanocortin agonist, but its balance of activity favors MC4R/MC3R (central) over MC1R (skin) relative to its parent compound Melanotan-II. MT-II activates MC1R strongly (producing the tanning effect it was originally developed for), whereas PT-141 has comparatively less MC1R engagement - though enough residual MC1R activity remains to cause dose-related hyperpigmentation with repeated use.

    Central Mechanism - The MC4R Arousal Pathway

    MC4R-expressing neurons in the paraventricular nucleus of the hypothalamus (PVN) are the critical substrate. When PT-141 activates these neurons:

    1. Downstream oxytocinergic signaling from PVN MC4R neurons is a proposed contributor to the arousal response, based on the broader melanocortin literature (note: Molinoff et al., 2003 [PMID 12851303] documented hypothalamic neuronal activation via c-Fos and erections in animals and men, not direct oxytocin measurement)
    2. Medial preoptic area (MPOA) activation drives sexual motivation and approach behavior
    3. Pro-erectile output to sacral autonomic ganglia via spinal cord pathways facilitates genital vascular response in men
    4. Dopaminergic activation in mesolimbic reward circuits amplifies the subjective "interest" component of arousal

    This pathway is upstream of the peripheral vascular machinery that PDE5 inhibitors target. A user with intact peripheral erectile function but poor central arousal - increasingly common in men on SSRIs, finasteride post-syndrome patients, or simply men with stress-driven low libido - is the archetype who responds to PT-141 when PDE5 inhibitors alone have failed.

    Why the Sex-Independent Effect

    Unlike testosterone (which drives libido through androgen receptor signaling and is sex-specific) or estradiol (which supports female sexual function via different pathways), the MC4R arousal mechanism is relatively sex-agnostic. PT-141 produces measurable effects on sexual motivation in both men and women because the PVN MC4R architecture is conserved across sexes. This is why the same 1.75 mg Vyleesi dose works in premenopausal women with HSDD and the same molecule is used off-label by men at 1-2 mg doses.

    Onset, Duration, and Pharmacokinetics

    Following subcutaneous injection of 1.75 mg bremelanotide, peak plasma concentrations occur at approximately 1 hour with a terminal half-life of about 2.7 hours (Vyleesi FDA prescribing information; PK characterized in Clayton et al., 2016 [PMID 27181790]). Subjective sexual effects typically begin 30-60 minutes post-injection and persist for 4-8 hours. This contrasts with intranasal bremelanotide (an earlier formulation that was discontinued in part due to blood pressure elevation concerns in clinical trials).

    The short half-life means PT-141 is used on-demand, not chronically. This pharmacology is deliberately similar to PDE5 inhibitors - take it when needed, don't dose it daily - and distinguishes it from libido-improving interventions like testosterone replacement that require ongoing therapy.

    Why MC4R Activation Also Suppresses Appetite

    The paraventricular nucleus MC4R pathway is simultaneously the central satiety circuit. Rare genetic MC4R loss-of-function mutations cause severe early-onset obesity; pharmacologic MC4R activation modestly suppresses appetite. This dual effect is why PT-141 users often report mild nausea and transient appetite suppression as side effects - they are direct pharmacodynamic consequences of MC4R activation, not off-target effects.

    Studied for

    • Female sexual dysfunction
    • Male erectile dysfunction
    • HSDD
    • Melanocortin signaling

    Benefits listed

    • Sexual desire enhancement
    • HSDD treatment
    • Erectile dysfunction (central mechanism)
    • Non-hormonal approach

    02Research

    Free with email

    What the research shows

    No research bench grades PT-141 (Bremelanotide) yet. Benches compare compounds people pair, with the evidence for each.

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    03Safety

    PT-141 side effects and interactions

    Side effects

    Low risk

    Stop use if

    • Uncontrolled hypertension
    • Cardiovascular disease
    • Taking oral naltrexone for alcohol or opioid addiction

    Common

    • Nausea
    • Flushing
    • Headache
    • Injection site reactions

    Less common

    • Blood pressure changes (transient)
    • Darkening of skin/gums (with repeated use)

    Who should not use it

    Contraindications

    PT-141 / bremelanotide is contraindicated or requires extreme caution in:

    • Uncontrolled hypertension (SBP >160 or DBP >100) — the transient blood pressure elevation PT-141 produces is additive to an already elevated baseline; may produce clinically significant hypertension
    • Established cardiovascular disease — prior MI, stroke, heart failure, significant coronary artery disease, or ongoing unstable angina
    • Significant peripheral vascular disease
    • Pregnancy — no established safety data; MC4R activation during pregnancy has theoretical effects on fetal development
    • Breastfeeding — no established safety data
    • Known hypersensitivity to bremelanotide or any excipient
    Read all the contraindications and cautionsShow less

    Relative cautions (use with supervision and monitoring):

    • Controlled but documented hypertension — verify BP is consistently <140/90 before each dose, monitor for 4 hours post-dose during initial uses
    • History of syncope or vasovagal reactions
    • Concurrent use of PDE5 inhibitors (sildenafil, tadalafil, vardenafil) — cumulative blood pressure effects; separate dosing by 2+ hours when combining
    • Concurrent use of sympathomimetics (decongestants, high-dose caffeine, pre-workouts containing yohimbine or DMHA)
    • Personal or strong family history of melanoma — theoretical concern about MC1R activation and pigmented lesion stimulation
    • Fitzpatrick skin type I-II users planning frequent use — pigmentation changes are more visible and develop faster
    • Active gastrointestinal disease — the nausea effect may be poorly tolerated
    • Users on MAO inhibitors — theoretical pharmacodynamic concerns; avoid combination
    • Active psychiatric instability — sexual function is complex psychologically; medicalizing an arousal issue that is primarily psychological is not appropriate

    Drug-drug interactions:

    • Cytochrome P450 substrate interactions — PT-141 is eliminated via proteolytic degradation rather than hepatic CYP metabolism, so direct P450 interactions are minimal
    • Antihypertensive medications — Users on antihypertensives should monitor for breakthrough elevations in the post-injection window; the PT-141 blood pressure effect may overcome modest antihypertensive coverage
    • Opioids — Increased nausea when combined; additive CNS depression in higher doses

    Discontinuation triggers:

    • Any new or changing pigmented skin lesion
    • Persistent blood pressure elevation beyond the 12-hour post-dose window
    • Chest pain, shortness of breath, or other cardiovascular symptoms following dosing
    • Severe intractable nausea not controllable with standard anti-emetic measures
    • Any signs of hypersensitivity or systemic allergic reaction

    Interactions

    4 pairings in our record: 1 to avoid, 2 with a caution and 1 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.

    • Oral naltrexone

      Avoid

      Per the Vyleesi (bremelanotide) FDA label, bremelanotide can significantly lower the systemic exposure of orally administered naltrexone, which may cause naltrexone treatment failure. The label says to avoid oral naltrexone products intended to treat alcohol or opioid addiction; it does not address low-dose naltrexone.

    • Melanotan 2

      Caution

      Both are melanocortin-receptor agonists - stacking is redundant for sexual function and compounds MC1R-driven hyperpigmentation and mole/freckle darkening. Avoid running them together.

    • Viagra/Cialis (PDE5 inhibitors)

      Caution

      Bremelanotide transiently RAISES blood pressure and lowers heart rate - it is not a vasodilator, so an 'additive hypotension' concern is incorrect. This is the most common off-label male-ED stack and is not FDA-contraindicated, but monitor blood pressure and separate dosing by 2+ hours.

    • Oxytocin

      Synergistic

      Complementary central mechanisms; MC4R activation can drive downstream oxytocinergic signaling. Pairing is anecdotal only - no controlled combination data.

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

    Order Bloodwork

    04Dosing

    Free with email

    PT-141 dosage and protocols

    Dose range
    500–2,000 mcg (0.5–2 mg) per dose
    Dosing
    As needed, 45 minutes before sexual activity; max once per 24 hours, max 8 doses/month
    Common vials
    2mg, 10mg

    Unlock the dosing protocols

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • Dose, route, how often and how long
    • A titration schedule
    • Beginner, intermediate and advanced protocols
    • Reconstitution and handling notes

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    05Prices

    PT-141 (Bremelanotide) prices

    5 listings from 4 vendors, opening in the Featured order.

    Pack prices
    $34.99 to $44.99
    Lowest per mg
    $3.50/mg
    Vendors
    4
    Listings
    5 (vial, nasal)

    Prices as the vendors list them, last recorded 8 October 2026.

    Form
    Sort
    PT-141 (Bremelanotide) listings, in Featured order
    VendorProductPriceBuy

    BH-141 10mg Research Atomizer

    nasal, 10mL

    Out of stock

    $9.00/mg

    $89.99

    View BH-141 10mg Research Atomizer at BHG Labs

    PT-141 10mg

    vial, 1 vial

    In stock

    $3.70/mg

    $37.00

    Buy PT-141 10mg at Ion Peptide

    PT-141 10mg

    vial, 1 vial

    In stock

    $4.00/mg

    $39.99

    Buy PT-141 10mg at BioMyst Labs

    PT-141 10mg

    vial, 1 vial

    In stock

    $4.50/mg

    $44.99

    Buy PT-141 10mg at BioMyst Labs

    PT-141 10mg

    vial, 10mg vial

    In stock

    $3.50/mg

    $34.99

    Lowest per mg
    Buy PT-141 10mg at Half Nattys
    Vendors selling PT-141 (Bremelanotide)(4: trust score, certificates, payment, shipping)

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors

    Price history(5 days with a recorded price)
    Review PT-141 (Bremelanotide)

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with PT-141 (Bremelanotide).

    06Chemistry

    Chemistry and structure

    Molecular formula
    C50H68N14O10
    Molecular mass
    1025.18 g/mol
    CAS number
    189691-06-3
    IUPAC name
    Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
    Amino acid sequence
    Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH - a cyclic lactam heptapeptide: an N-terminal acetyl group, a side-chain Asp-to-Lys amide (lactam) ring, and a C-terminal carboxylic acid. Residues: N-acetyl-norleucine (Nle), Asp, His, D-Phe, Arg, Trp, Lys. Molecular formula C50H68N14O10 (average mass ~1025.2 g/mol). Standard one-letter codes do not fully apply because Nle (norleucine) is non-proteinogenic and Phe is present as the D-enantiomer. Bremelanotide (PT-141) is the ring-closed metabolite of Melanotan-II, differing only at the C-terminus: MT-II is a C-terminal amide (-NH2), PT-141 is the carboxylic acid (-OH).
    View on PubChem

    08Questions

    Frequently asked questions

    What is PT-141 (bremelanotide) and how does it work?

    PT-141, also known as bremelanotide, is a synthetic cyclic 7-amino-acid melanocortin receptor agonist that works centrally in the brain - specifically on MC4R-expressing neurons in the hypothalamus - to enhance sexual desire, arousal, and responsiveness. Unlike PDE5 inhibitors like sildenafil and tadalafil, which work peripherally in the corpus cavernosum to maintain erectile blood flow once arousal has already begun, PT-141 works upstream at the central arousal trigger itself. It was FDA-approved as Vyleesi in June 2019 for acquired generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use in men for erectile dysfunction and in both sexes for general libido enhancement is widespread in the peptide community.

    How is PT-141 different from Viagra or Cialis?

    The two classes work on completely different parts of the sexual response pathway. PDE5 inhibitors (Viagra/sildenafil, Cialis/tadalafil, Levitra/vardenafil) work peripherally - they inhibit the enzyme that breaks down cGMP in the corpus cavernosum, allowing sustained blood flow to maintain an erection once arousal is already present. PT-141 works centrally - it activates MC4R receptors in the brain's paraventricular nucleus to generate the arousal signal itself. This means PT-141 can address sexual dysfunction that PDE5 inhibitors cannot, such as low desire, arousal disorders, and ED from SSRI use or post-finasteride syndrome where the peripheral machinery is intact but the central trigger is not firing. Many users combine the two for additive central + peripheral effects.

    What is the best PT-141 dosage?

    For most users, 1.0-1.75 mg subcutaneously taken 45-60 minutes before sexual activity is the effective therapeutic window. The FDA-approved Vyleesi dose for female HSDD is 1.75 mg. First-time users should start at 0.5 mg to assess nausea tolerance, as nausea is the dose-limiting side effect affecting roughly 40% of users at full doses. Higher doses of 2.0 mg are used by some off-label users but show diminishing returns. Beyond 2 mg, nausea and blood pressure effects scale faster than sexual response. Maximum frequency is once per 24 hours, with the FDA labeling capping monthly use at 8 doses (primarily to limit cumulative cardiovascular exposure and hyperpigmentation).

    Can men use PT-141 for erectile dysfunction?

    Yes, off-label. PT-141 was studied for male ED alongside the female HSDD program. Early Phase 1/2 data showed statistically significant erectile responses: Rosen 2004 (subcutaneous) in healthy men and in men with an inadequate response to Viagra, and Diamond 2004 (intranasal) in Viagra-responsive ED patients. These were small early-phase trials, not a pivotal Phase 3 program, and Palatin Technologies did not pursue a male-ED approval. Typical off-label male dosing is 1-1.75 mg SC 45-60 minutes before activity. Men who have failed PDE5 inhibitor monotherapy, men on SSRIs with blunted central arousal, and men with post-finasteride syndrome are the populations most often cited as responders, though evidence in those specific groups is anecdotal. Many men combine PT-141 with a PDE5 inhibitor for additive central + peripheral coverage.

    What are the side effects of PT-141?

    The most common side effect is nausea, affecting roughly 40% of users in clinical trials. It usually starts 30-60 minutes after injection and resolves within 2-4 hours. Other common effects are facial flushing, injection site reactions, headache, and a transient blood pressure elevation of +6-8 mmHg systolic that peaks at 2-4 hours and resolves by 12 hours. With repeated use, dose-dependent hyperpigmentation (darker freckles, new moles, facial pigmentation) can occur due to residual MC1R activity - this is the most important long-term side effect to monitor. Any new or changing pigmented skin lesion should prompt dermatology evaluation. PT-141 is contraindicated in uncontrolled hypertension and established cardiovascular disease due to the blood pressure effect.

    Does PT-141 cause permanent tanning or moles?

    PT-141 has significantly less MC1R activity than its parent compound Melanotan-II, but residual MC1R agonist effect is present and can cause dose-dependent hyperpigmentation with repeated use. This typically shows as darker or new freckles, enlarging existing moles, diffuse facial pigmentation, and darker areas on gums or areolae. The pigmentation is generally slowly reversible with discontinuation - melanocyte turnover takes months - but some users experience persistent darker patches. Users who plan frequent use should do monthly skin self-exams, get annual dermatology visits for full-body skin checks, consider a 4-week washout every 3-4 months, and use aggressive SPF 50+ sun protection since sun-exposed skin pigments more dramatically under PT-141 influence.

    How long does PT-141 last?

    Following subcutaneous injection, peak plasma concentrations occur at approximately 1 hour, with a half-life of about 2.7 hours. Subjective sexual effects typically begin 30-60 minutes post-injection and persist for 4-8 hours. This makes PT-141 an on-demand drug similar to PDE5 inhibitors - not daily dosed like SSRIs, testosterone replacement, or chronic peptide protocols. Some users report lingering mood and arousal effects up to 12 hours post-dose, but the primary sexual-response window is roughly 1-6 hours after injection. Blood pressure effects typically normalize by 12 hours. The short half-life is deliberately engineered to prevent the drug from accumulating in plasma and to minimize cumulative exposure.

    Can I stack PT-141 with other peptides or medications?

    Yes, with care. The most common stacks are PT-141 + PDE5 inhibitors for male ED (separating doses by 2+ hours to manage cumulative blood pressure effects), PT-141 + oxytocin for enhanced bonding/emotional response, and PT-141 + testosterone replacement for hypogonadal men where central arousal remains blunted after hormonal optimization. PT-141 does not interact with tissue-repair peptides like BPC-157 or TB-500 - those operate on entirely different pathways. Avoid stacking PT-141 with Melanotan-II (dramatically compounds hyperpigmentation), high-dose stimulants (additive sympathomimetic load), or sympathomimetic decongestants (additive blood pressure effect). Also avoid combining with oral naltrexone taken for alcohol or opioid addiction, which the Vyleesi label warns bremelanotide can render less effective; the label does not address low-dose naltrexone.

    Is PT-141 legal?

    Yes, in the United States, bremelanotide is legal as Vyleesi - the FDA-approved prescription product for HSDD in premenopausal women, available through licensed physicians. 'PT-141' in the research-peptide market is the same molecule but sold under a research-only classification through peptide research suppliers. Research-grade product is not FDA-approved for human use and typical disclaimers specify research applications only. Users who want the fully legal, medically supervised pathway should pursue Vyleesi through a licensed physician. Users who choose the research-grade pathway should source from vendors with third-party purity testing and understand the quality-control and legal implications. See our best vendors guide for 2026 for a curated list of research peptide suppliers and peptide-friendly clinical practices.

    Can PT-141 help with low libido from SSRIs or post-finasteride syndrome?

    PT-141 is one of the more promising interventions for sexual dysfunction secondary to SSRIs (selective serotonin reuptake inhibitor use) and post-finasteride syndrome (PFS), though formal clinical trial evidence in these specific populations is limited. SSRIs and finasteride both disrupt central arousal circuits - SSRIs through serotonergic suppression of dopaminergic arousal pathways, finasteride through 5-alpha-reductase inhibition affecting neurosteroid levels in sexually-relevant CNS regions. Because PT-141 activates the MC4R arousal pathway upstream of these disrupted circuits, it can sometimes bypass the blockade. Anecdotal reports and the mechanistic rationale are encouraging; formal evidence is limited to case series. Users in this category should work with a physician experienced in sexual medicine to evaluate the risk-benefit ratio relative to adjusting the offending medication.

    How many vendors sell PT-141 (Bremelanotide), and what does it cost per mg?

    3 of the vendors BodyHackGuide tracks list PT-141 (Bremelanotide) (5 listings). Among BodyHackGuide's PT-141 (Bremelanotide) listings recorded as in stock with a milligram count, the lowest price per milligram is $3.50/mg at Half Nattys and the median is $3.85/mg. The PT-141 (Bremelanotide) prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a PT-141 (Bremelanotide) listing is dated 8 October 2026.

    Which vendors have third-party COAs for PT-141 (Bremelanotide) on file at BodyHackGuide?

    BodyHackGuide holds 91 third-party certificate records for PT-141 (Bremelanotide), from ResearchChemHQ and Half Nattys and BHG Labs. An editor has read 4 of BodyHackGuide's 91 certificate records for PT-141 (Bremelanotide) and recorded the laboratory, the compound and the test date as printed on each. The laboratories named on BodyHackGuide's PT-141 (Bremelanotide) certificate records are Janoshik Analytical, Freedom Diagnostics Testing and ILS Laboratories, and the newest test date on them is 2 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free